Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy - Takeaways - MDSpire

Maternal and Fetal Delivery of Risdiplam Provides Partial Rescue in the SMNΔ7 Mouse Model of Spinal Muscular Atrophy

  • By

  • Emma R. Sutton

  • Ariane Beauvais

  • Rebecca Yaworski

  • Hugh J. McMillan

  • Rashmi Kothary

  • July 15, 2026

Share

  • 1

    Spinal muscular atrophy (SMA) is caused by mutations in the SMN1 gene, leading to reduced SMN protein levels essential for motor neuron health.

  • 2

    Current disease-modifying therapies for SMA are FDA-approved for postnatal use only, highlighting a gap in treatment for prenatal SMA onset.

  • 3

    In utero therapy with risdiplam in SMA mouse models has shown promise in improving motor function and survival compared to postnatal treatment.

  • 4

    A recent case study reported a pregnant woman treated with risdiplam, resulting in her child showing no clinical signs of SMA at 30 months.

  • 5

    Establishing prenatal therapy for SMA could bridge the therapeutic gap and enhance treatment efficacy during critical developmental windows.

Original Source(s)

Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy

  • by Emma R. Sutton, Ariane Beauvais, Rebecca Yaworski, Hugh J. McMillan, Rashmi Kothary

  • July 15, 2026

Related Content

Imaging patterns of hemorrhagic transformation after tenecteplase versus alteplase in real-world practice

Small extracellular vesicles proteome reveals persistent inflammatory and coagulopathic dysregulation in long-COVID

Musical Museum: an integrative approach to emotional, intellectual and social stimulation for individuals with Alzheimer’s disease and related disorders and their caregivers